Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
Phase 2 Completed
150 enrolled
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Phase 2 Completed
51 enrolled
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Phase 2 Completed
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Completed
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Phase 1 Terminated
8 enrolled
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Phase 3 Completed
595 enrolled
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Phase 2 Completed
104 enrolled 6 charts
EMN-03
Phase 3 Completed
110 enrolled
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 2 Completed
147 enrolled 6 charts
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Phase 3 Completed
899 enrolled
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Withdrawn
Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years
Phase 3 Unknown
64 enrolled